scholarly journals A maple syrup extract alters lipid metabolism in obese type 2 diabetic model mice

2019 ◽  
Vol 16 (1) ◽  
Author(s):  
Tsudoi Toyoda ◽  
Asuka Kamei ◽  
Tomoko Ishijima ◽  
Keiko Abe ◽  
Shinji Okada
Keyword(s):  
Lipid Metabolism ◽  
Bile Acid ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Diabetic Mouse ◽  
Total Bile Acid ◽  
Maple Syrup ◽  
Bile Acid Level ◽  
Cholesterol Levels ◽  
Expression Of Genes

Abstract Background Some polyphenols are known to improve the symptoms of diabetes. In the present study, we investigated the effects of a polyphenol-rich extract of maple syrup (MSx) on a diabetic mouse model. Methods KK-Ay mice were fed a normal or 0.05% MSx-supplemented diet for 42 days. Body weight, food intake, serum biochemical parameters, and fecal total bile acid were measured. Gene expression of liver and epididymal white adipose tissue (WAT) and cecal microbiota were analyzed. Data were analyzed with an unpaired two-tailed Student’s t test or Welch’s t test according to the results of the F test. Results Serum low-density lipoprotein cholesterol levels were significantly reduced in mice that consumed MSx. Hepatic genes related to fatty acid degradation and cholesterol catabolism were upregulated in mice that consumed MSx. In contrast, the expression of genes related to lipid metabolism in WAT was unaffected by the intake of MSx. There were no significant differences between the two groups in terms of total bile acid level in the feces and the relative abundance of bacteria in the cecum. Conclusion Our results primarily indicate that MSx can help alleviate one of the symptoms of dyslipidemia.

scholarly journals Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Lu Yu ◽  
Jing Liu ◽  
Xiaojun Huang ◽  
Qian Jiang
Keyword(s):  
Lipid Metabolism ◽  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Chronic Phase ◽  
Vascular Diseases ◽  
Free Survival ◽  
Cholesterol Levels ◽  
The Mean

AbstractTo explore the differences in glucose-lipid metabolism profiles among the 3 TKIs, we designed a retrospective study to compare the onset of hyperglycaemia, hypertriglyceridemia, hypercholesterolemia and hyper-low density lipoprotein (LDL)-cholesterolemia in the patients with normal baseline glucose-lipid profiles and had no medical record of cardio- or cerebro-vascular diseases and/or metabolic syndrome diseases, and identify variables associated with them. 370 chronic myeloid leukaemia patients receiving dasatinib, nilotinib or imatinib therapy ≥3 months were retrospectively reviewed. During TKI-therapy, the mean fasting glucose, triglyceride, cholesterol, and LDL-cholesterol levels increased significantly in both dasatinib and nilotinib cohorts compared with the imatinib cohort. In multivariate analyses, dasatinib was the factor significantly associated with both poor hyperglycaemia- and hypertriglyceridemia-free survival. In addition, nilotinib was significantly associated with more occurrences of hyperglycaemia and hypercholesterolemia; increasing age was significantly associated with more occurrences of hyperglycaemia and hypertriglyceridemia. We concluded that dasatinib, similar to nilotinib, has the adverse impact on glucose-lipid metabolism compared with imatinib.

scholarly journals LKB1 is required for hepatic bile acid transport and canalicular membrane integrity in mice

2011 ◽  
Vol 434 (1) ◽  
pp. 49-60 ◽  
Author(s):  
Angela Woods ◽  
Amanda J. Heslegrave ◽  
Phillip J. Muckett ◽  
Adam P. Levene ◽  
Melanie Clements ◽  
...  
Keyword(s):  
Bile Acid ◽  
Low Density Lipoprotein ◽  
Critical Role ◽  
Membrane Integrity ◽  
Density Lipoprotein ◽  
Failure To Thrive ◽  
Hepatic Function ◽  
Canalicular Membrane ◽  
Cholesterol Levels ◽  
Regulation Of Metabolism

LKB1 is a ‘master’ protein kinase implicated in the regulation of metabolism, cell proliferation, cell polarity and tumorigenesis. However, the long-term role of LKB1 in hepatic function is unknown. In the present study, it is shown that hepatic LKB1 plays a key role in liver cellular architecture and metabolism. We report that liver-specific deletion of LKB1 in mice leads to defective canaliculi and bile duct formation, causing impaired bile acid clearance and subsequent accumulation of bile acids in serum and liver. Concomitant with this, it was found that the majority of BSEP (bile salt export pump) was retained in intracellular pools rather than localized to the canalicular membrane in hepatocytes from LLKB1KO (liver-specific Lkb1-knockout) mice. Together, these changes resulted in toxic accumulation of bile salts, reduced liver function and failure to thrive. Additionally, circulating LDL (low-density lipoprotein)-cholesterol and non-esterified cholesterol levels were increased in LLKB1KO mice with an associated alteration in red blood cell morphology and development of hyperbilirubinaemia. These results indicate that LKB1 plays a critical role in bile acid homoeostasis and that lack of LKB1 in the liver results in cholestasis. These findings indicate a novel key role for LKB1 in the development of hepatic morphology and membrane targeting of canalicular proteins.

scholarly journals Efficacy of statin therapy in primary care — OZIRKA trial: population study on the effectiveness of Ozalex (rosuvastatin) in the treatment of patients with lipid metabolism disorders and hypercholesterolemia in different categories of patients

HYPERTENSION ◽  
2020 ◽  
Vol 13 (6) ◽  
pp. 5-14
Author(s):  
Yu.M. Sirenko ◽  
O.O. Torbas ◽  
S.M. Kushnir
Keyword(s):  
Primary Care ◽  
Lipid Metabolism ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Cholesterol Levels ◽  
Lipid Metabolism Disorders

Background. In Ukraine, the number of statin prescriptions in recent years remains relatively low. A large-scale Ukrainian study OZIRKA would disprove some of the myths and demonstrate that long-term therapy with one of the most effective statins — rosuvastatin — in moderate and high doses is safe and effective in a large cohort of patients during primary care. The purpose of the study was to demonstrate the effect of Ozalex (rosuvastatin) on lipid and cholesterol levels in patients with lipid metabolism disorders and hypercholesterolemia. Materials and methods. The study was planned as a prospective, open-label, population one. Recruitment of patients was done from March to December 2019. The analysis of the study data was conducted from June to November 2020. All patients had to receive rosuvastatin (Ozalex, Kusum Pharm, Ukraine) at a dose of 10 or 20 mg. Results. A total of 20,000 patients from all over Ukraine were planned to be included in the study. The full follow-up period was completed by 18,100 patients, of whom 17,530 had all the necessary data, so they were included in the final analysis. The mean follow-up period was 2.2 months. During the two months of follow-up, patients on average showed a significant reduction in total cholesterol levels — by 28 % (p < 0.001), low-density lipoprotein cholesterol — by 34 % (p < 0.001), triglycerides — by 25 % (p < 0.001). Increasing the dose of rosuvastatin from 10 to 20 mg after the first visit resulted in an additional reduction in low-density lipoprotein cholesterol by approximately 40 %. The fasting blood glucose level in the patients in this study reduced significantly, from 5.70 ± 0.01 mmol/l to 5.23 ± 0.01 mmol/l (significance of the dynamics of p < 0.001). Conclusions. Ozalex, manufactured by Kusum Pharm (Ukraine), is a highly effective generic drug of rosuvastatin, which has a neutral effect on glucose metabolism and allows achieving good control of blood lipids at the stage of primary care.

The Lipid-Lowering Effects of 3-Hydroxy-3-Methylglutaric Acid and Bile Acid Drainage in WHHL Rabbits

1984 ◽  
Vol 67 (4) ◽  
pp. 439-444 ◽  
Author(s):  
J. L. M. Van Niekerk ◽  
Th. Hendriks ◽  
J. A. Gevers Leuven ◽  
L. Havekes ◽  
H. H. M. De Boer
Keyword(s):  
Bile Acid ◽  
Serum Cholesterol ◽  
Familial Hypercholesterolaemia ◽  
Recent Literature ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Working Mechanism ◽  
Acid Drainage ◽  
Cholesterol Levels

1. The effect of 3-hydroxy-3-methylglutaric acid (HMG) on serum cholesterol levels was investigated in Watanabe heritable hyperlipidaemic (WHHL) rabbits. 2. Oral administration of HMG resulted in a reduction of serum cholesterol by 39%. 3. Bile acid drainage, by means of either cholestyramine medication or partial ileal bypass (PIB) surgery, also led to significant reductions in circulating cholesterol, by 35 and 59% respectively. 4. Intraperitoneal injection of HMG after PIB surgery further reduced serum cholesterol by 35%. 5. Fibroblasts from the WHHL rabbits did not show high-affinity binding, uptake or degradation of 125I-labelled low density lipoprotein (LDL). 6. The working mechanism of these lipid-lowering therapies in WHHL rabbits is discussed in relation to recent literature. 7. The significant reductions in circulating cholesterol induced by HMG warrant further investigation into the use of this compound in the management of familial hypercholesterolaemia.

scholarly journals Differences in the Effects of Anthocyanin Supplementation on Glucose and Lipid Metabolism According to the Structure of the Main Anthocyanin: A Meta-Analysis of Randomized Controlled Trials

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 2003
Author(s):  
Risa Araki ◽  
Akira Yada ◽  
Hirotsugu Ueda ◽  
Kenichi Tominaga ◽  
Hiroko Isoda
Keyword(s):  
Lipid Metabolism ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Resistance Index ◽  
Lipoprotein Cholesterol ◽  
Controlled Trials ◽  
Oh Groups ◽  
Chemical Structures ◽  
Glucose And Lipid Metabolism

The effectiveness of anthocyanins may differ according to their chemical structures; however, randomized clinical controlled trials (RCTs) or meta-analyses that examine the consequences of these structural differences have not been reported yet. In this meta-analysis, anthocyanins in test foods of 18 selected RCTs were categorized into three types: cyanidin-, delphinidin-, and malvidin-based. Delphinidin-based anthocyanins demonstrated significant effects on triglycerides (mean difference (MD): −0.24, p < 0.01), low-density lipoprotein cholesterol (LDL-C) (MD: −0.28, p < 0.001), and high-density lipoprotein cholesterol (HDL-C) (MD: 0.11, p < 0.01), whereas no significant effects were observed for cyanidin- and malvidin-based anthocyanins. Although non-significant, favorable effects on total cholesterol (TC) and HDL-C were observed for cyanidin- and malvidin-based anthocyanins, respectively (both p < 0.1). The ascending order of effectiveness on TC and LDL-C was delphinidin-, cyanidin-, and malvidin-based anthocyanins, and the differences among the three groups were significant (both p < 0.05). We could not confirm the significant effects of each main anthocyanin on glucose metabolism; however, insulin resistance index changed positively and negatively with cyanidin- and delphinidin-based anthocyanins, respectively. Therefore, foods containing mainly unmethylated anthocyanins, especially with large numbers of OH groups, may improve glucose and lipid metabolism more effectively than those containing methylated anthocyanins.

scholarly journals Genetic variation of RNF145 gene and blood lipid levels in Xinjiang population, China

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jing Ming ◽  
Xian Wei ◽  
Min Han ◽  
Dilare Adi ◽  
Jialin Abuzhalihan ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Ring Finger ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lipid Profiles ◽  
Cholesterol Levels ◽  
General Linear Model Analysis ◽  
Confounding Variables ◽  
Before And After ◽  
Detection Response

AbstractDyslipidemia is one of the main risk factors for coronary heart disease (CHD). The E3 ubiquitin ligase which is encoded by the ring finger protein 145 (RNF145) gene is very important in the mediation of cholesterol synthesis and effectively treats hypercholesterolemia. Thus, the purpose of the present research is to investigate the connection between the polymorphism of the RNF145 gene and cholesterol levels in the populations in Xinjiang, China. A total of 1396 participants (Male: 628, Female: 768) were included in this study for genetic analysis of RNF145 gene, and we used the modified multiple connection detection response (iMLDR) technology to label two SNPs (rs17056583, rs12188266) of RNF145 genotyping. The relationship between the genotypes and the lipid profiles was analyzed with general linear model analysis after adjusting confounding variables. Through the analysis of the two SNPs in RNF145 gene, we discovered that both rs17056583 and rs12188266 were related to total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations (All P < 0.001). In addition, the association of rs17056583 and rs12188266 with lipid profiles concentrations is still statistically significant after multivariate adjustment of sex, age, smoking, obesity, drinking, diabetes, hypertension and lipid profiles. Meanwhile, we also found that rs17056583 was associated with high triglycerides concentrations before and after adjustment (All P < 0.001). Our study shows that both rs17056583 and rs12188266 SNPs of RNP145 gene are related to TC and LDL-C concentrations in Xinjiang population.

scholarly journals The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia

Genes ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 66
Author(s):  
Alexey Meshkov ◽  
Alexandra Ershova ◽  
Anna Kiseleva ◽  
Evgenia Zotova ◽  
Evgeniia Sotnikova ◽  
...  
Keyword(s):  
Familial Hypercholesterolemia ◽  
Low Density Lipoprotein ◽  
Significant Proportion ◽  
Density Lipoprotein ◽  
Genetic Diagnostics ◽  
Atherosclerotic Cardiovascular Disease ◽  
Gene Variants ◽  
Systematic Analysis ◽  
Pcsk9 Gene ◽  
Cholesterol Levels

Familial hypercholesterolemia (FH) is a common autosomal codominant disorder, characterized by elevated low-density lipoprotein cholesterol levels causing premature atherosclerotic cardiovascular disease. About 2900 variants of LDLR, APOB, and PCSK9 genes potentially associated with FH have been described earlier. Nevertheless, the genetics of FH in a Russian population is poorly understood. The aim of this study is to present data on the spectrum of LDLR, APOB, and PCSK9 gene variants in a cohort of 595 index Russian patients with FH, as well as an additional systematic analysis of the literature for the period of 1995–2020 on LDLR, APOB and PCSK9 gene variants described in Russian patients with FH. We used targeted and whole genome sequencing to search for variants. Accordingly, when combining our novel data and the data of a systematic literature review, we described 224 variants: 187 variants in LDLR, 14 variants in APOB, and 23 variants in PCSK9. A significant proportion of variants, 81 of 224 (36.1%), were not described earlier in FH patients in other populations and may be specific for Russia. Thus, this study significantly supplements knowledge about the spectrum of variants causing FH in Russia and may contribute to a wider implementation of genetic diagnostics in FH patients in Russia.

Sign in / Sign up

Export Citation Format

Share Document